| Document and Entity Information | Jun. 28, 2024 |
| Cover [Abstract] | |
| Document Type | 8-K |
| Amendment Flag | false |
| Document Period End Date | Jun. 28, 2024 |
| Entity File Number | 001-39990 |
| Entity Registrant Name | Elicio Therapeutics, Inc. |
| Entity Central Index Key | 0001601485 |
| Entity Incorporation, State or Country Code | DE |
| Entity Tax Identification Number | 11-3430072 |
| Entity Address, Address Line One | 451 D Street, 5th Floor |
| Entity Address, City or Town | Boston |
| Entity Address, State or Province | MA |
| Entity Address, Postal Zip Code | 02210 |
| City Area Code | 857 |
| Local Phone Number | 209-0050 |
| Title of 12(b) Security | Common Stock, $0.01 par value per share |
| Trading Symbol | ELTX |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | true |
| Entity Ex Transition Period | false |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
